08/31/2009 - A man and woman have filed a suit against Bayer, alleging they were not warned of possible side effects in a drug used to control bleeding in coronary artery bypass grafting. More>>>

05/12/2009 - It is a a major breakthrough in combating fraud and corruption: At today's annual general shareholders meeting of Germanys Bayer AG, a former pharmaceutical employee intends to unveil severe corruption practices within BAYER. More>>>

01/09/2009- A Calgary law firm has launched a class-action suit against pharmaceutical giant Bayer Inc. for its drug Trasylol, alleging it causes kidney failure, stroke and other serious health problems. More>>>

01/08/2009- For as long as large pharmaceutical drug companies have been around illegal kickbacks have been awarded to serve as an incentive for doctors to use specific drugs. These kickbacks have attributed to numerous cases where a patient has suffered due to their doctor recommending a drug that they received a kickback for. More>>>

12/09/2008- If you recently developed kidney failure and have also undergone heart bypass surgery, the Trasylol may have been the cause. For people who were administered Trasylol during their heart bypass surgery may have caused their kidney failure. Trasylol, manufactured by Bayer Pharmaceuticals, has been linked to cause kidney complications and failure. More>>>

12/08/2008- Bayer voluntarily withdrew Trasylol from the market after a clinical trial found patients treated with the drug were 53 per cent more likely to die than those treated with other anti-bleeding medications. More>>>

12/04/2008- A class action lawsuit has been filed in Canada against Bayer involving their heart bypass surgery injection Trasylol. The lawsuit was filed the day after a new study was released confirming that individuals who are given the injection face an increased risk of death. More>>>

12/02/2008- A new study casts more doubt on the safety of the drug Trasylol (aprotinin), used to limit bleeding in patients undergoing surgery. Trasylol is already the subject of controversy in the United States, where it was removed from the market in 2007. In the new study, Canadian and Australian researchers reviewed findings from 49 randomized clinical trials. They concluded that Trasylol posed a higher risk of death for patients than other anti-bleeding drugs, called lysine analogues. More>>>

10/09/2008- Drug maker Bayer AG has recalled all remaining stocks of the anti-bleeding medication Trasylol (aprotinin) from the U.S. market after a New England Journal of Medicine Study demonstrated that the drug increased heart surgery patients' risk of death by 53 percent. More>>>

10/08/2008- A new lawsuit has been filed on behalf of two heart surgery patients who received an injection known as Trasylol before their operations to control bleeding. The suit seeks damages for acute renal failure requiring dialysis caused by the injection. More>>>

09/25/2008- Have you recently experienced a lack of being able to urinate, or excessive urination, swelling, nausea, or drastic mood changes. If so you might be suffering from acute Kidney failure, in which your kidneys have suddenly lost the ability to dispose of waste. More>>>

09/10/2008- In the recent decade a push for dietary health has seen a big increase in importance as the obesity rate has increased tremendously over the entire world. Whether it is because our fast pace world promotes fast eating, our society has expanded its waste line tremendously. More>>>

09/04/2008- Open heart surgery is the most common surgery in the United States. This might sound alarming and might pose certain questions as to why this is occurring. The need for a bypass surgery is because there is a blockage in your arteries that is cutting off the circulation of blood. More>>>

08/30/2008- Acute Kidney Failure, also known as renal failure, entails the abrupt loss of the use of the kidneys to excrete waste and urine. Some of the causes of acute kidney failure are infections of the kidney, obstruction of the kidney track, decreased blood flow, and other disorders that cause clotting within the kidneys blood vessels. More>>>

08/20/2008- Heart bypass surgery is one of the most invasive surgeries to date because the chest is wide open and the heart is stopped. Common symptoms that indicate needing heart bypass surgery is severe chest pain. More>>>

08/19/2008- Trasylol, a medicine manufactured by Bayer which also goes by the name aprotinin, has been widely used since the 1990s. It was used as a medicine given during heart bypass surgery to reduce bleeding and the need for blood transfusions. More>>>

08/14/2008- The FDA's delay in taking Trasylol off the market led to 1,000 deaths each month for a year and a half, according to the doctor who first alerted the agency to the dangers of the drug. More>>>

08/05/2008- Trasylol is medication that is administered by means of an injection. Its objective is to reduce bleeding during surgery by slowing down a process that causes blood clots. Although this drug provides a seemingly positive and essential attribute to surgery, there are many problems that can result from such a strong drug. More>>>

08/01/2008- Acute kidney failure is a serious condition in which a loss in function is found in the kidneys that no longer allows them to remove urine and other waste without also losing electrolytes. Acute kidney failure happens very suddenly and is dangerous so it is considered a medical emergency. More>>>

07/28/2008 - Trasylol was a leading drug used in heart surgeries to limit the amount of blood. Such heart surgeries include open heart, single double and triple bypasses, as well as transplants. However, Trasylol was taken off the market in November of 2007 because it was linked to cause kidney failure, heart damage, strokes, and death. More>>>

07/03/2008- The crux of the argument that FDA approval of a drug should preempt state lawsuits over that drug is that it should be experts at the FDA who decide whether a drug is safe and what warnings that drug’s label should carry.  More>>>

06/17/2008- Because Trasylol was approved so long ago, there are many people whose loved ones were affected by the drug but do not realize it. Barbara S. says her husband, Carson, had open heart surgery in 1998, but she is only now realizing that his serious health problems may have been caused by Trasylol. More>>>

06/08/2008- New York, NY: One of the lead authors of a pivotal Canadian study that most experts say will spell the end of Trasylol, has suggested that Bayer AG could have undertaken a similar study ten years ago. In that time, thousands have died. More>>>

05/30/2008- Earlier this month, Bayer announced that it was recalling remaining Trasylol stocks from the US market. The move comes after repeated studies found that patients given Trasylol during open heart surgery had a higher risk of kidney failure, strokes and death than patients given a different drug. More>>>

05/28/2008- In November of 2007, after initial reports were given to the Food & Drug Administration (FDA) Bayer AG, the maker of the drug Trasylol (also know as aprotinin), agreed to temporarily suspend sales and marketing of Trasylol. More>>>

05/26/2008-The Germany-based manufacturer is hedging its bets over its once-dominant anti-bleeding drug, even though most believe that the Canadian BART clinical trial has effectively sounded the death knell for a drug that has allegedly spelled death for thousands of heart patients. More>>>

05/23/2008- After repeated studies showed that patients who were given Trasylol had a higher risk of kidney failure. Bayer, maker of Trasylol, has started recalling remaining stocks of the drug in the US. Previously, Bayer had suspended marketing the drug, but had not recalled all stock of the drug. Meanwhile, the company faces lawsuits related to its handling of the drug. More>>>

05/22/2008- A new Canadian study confirms that people given Trasylol, a drug used to reduce bleeding during heart surgery, face a 53 percent increased risk of death. More>>>

05/21/2008- Results of the Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART), halted by the company [Bayer] last year, have now been published online May 15, 2008 in the New England Journal of Medicine, scheduled for its May 29, 2008 issue, confirming that aprotinin (Trasylol, Bayer Healthcare Pharmaceuticals), an antifibrinolytic agent designed to reduce major bleeding during coronary artery bypass graft (CABG), significantly increased the risk of death. More>>>

05/19/2008- An anti-bleeding drug probably will stay off the market, experts say, after a rigorous study found patients getting the medication during heart surgery were much more likely to die than patients given other drugs. More>>>

05/16/2008- Bayer AG will begin removing the remaining stock of the drug Trasylol, used to control bleeding, from warehouses and hospitals, the U.S. Food and Drug Administration said in a statement today. More>>>

05/16/2008- The results of a study published in the New England Journal of Medicine have confirmed preliminary findings that Bayer’s anti-bleeding medication Trasylol (aprotinin) dramatically increases a patient’s risk of death. The BART trial, as it was called, was halted when it became apparent that death rates were disproportionately higher for patients being given Trasylol. More>>>

05/16/2008- Trasylol is being removed from the market for good.  Bayer AG had suspended marketing of Trasylol, a drug used to prevent bleeding during heart surgery, in November, after a clinical trial found patients treated with Trasylol were dying at higher rates than others.  More>>>

05/16/2008- An expensive drug used to minimize severe bleeding during heart surgery actually significantly increased the risk that patients would die during surgery or in the 30 days following, a Canadian study comparing the drug to two far cheaper alternatives shows. More>>>

05/15/2008 - A new study could be the last nail in Trasylol's coffin. In a head-to-head comparison of Trasylol (aprotinin) and two other anti-bleeding meds, patients getting Trasylol during heart surgery were much more likely to die than patients on the other meds. More>>>

05/15/2008 - An anti-bleeding drug probably will stay off the market, experts say, after a rigorous study found patients getting the medication during heart surgery were much more likely to die than patients given other drugs. More>>>

05/15/2008 - Patients who received a drug commonly used to control bleeding during heart surgery were at a higher risk of dying, new research by the Ottawa Health Research Institute reveals. More>>>

05/14/2008 - A new Canadian study confirms that people given Trasylol, a drug used to reduce bleeding during heart surgery, face a 53 percent increased risk of death. More>>>

05/14/2008 - Bayer AG is removing remaining supplies of its heart-surgery drug Trasylol from the U.S. market after a long-awaited study found it raised the risk of death compared to two alternatives, U.S. regulators said on Wednesday. More>>>

05/09/2008 - Loretta M. says she is sure she was given Trasylol during her open heart surgeries because her doctor spoke about using blood-regulating drugs during surgery. She had two open heart surgeries and experienced serious side effects after both. Like many people, Loretta is upset that Trasylol was used despite the risks associated with the drug. More>>>

05/06/2008 - As Bayer AG continues to study the results of the Canadian BART trial on Trasylol, and whether or not those findings may compel the manufacturer to lobby health regulators as to the merits of re-marketing a now-vilified drug, its legal arm prepares for its day in court as lawsuits against Bayer mount. More>>>

04/29/2008 - Mark L. suffered kidney failure shortly after his open heart surgery. However, he does not know for sure if Trasylol was used. Mark is now trying to determine whether or not doctors gave him Trasylol to stop him from bleeding during surgery. More>>>

04/25/2008 - Germany's Bayer AG is facing 78 lawsuits in the United States linked to its Trasylol drug used to stem bleeding during open heart surgery, its chief executive said on Friday. More>>>

04/23/2008 - Eight lawsuits filed in a Florida federal court are seeking damages from Bayer AG over a controversial anti-bleeding drug. More>>>

04/20/2008 - Pharmaceutical giant Bayer AG has announced that it is withdrawing its drug Trasylol from the market in response to a request by the FDA, in the face of increasing evidence that the drug increases patients' risk of death. More>>>

04/20/2008- When Bayer AG convenes its annual stockholder's meeting on April 25th in Cologne, the German group Coalition against BAYER Dangers (CBG) will be on hand to introduce countermotions to the proceedings, one of which will focus on the history, and dangers of Trasylol (known as Aprotinin). More>>>

04/13/2008- Alice G. says that in the six years since her mother died, her family has struggled to understand what happened. With the recent news about Trasylol, Alice says she may have a better understanding of why her mother died. More>>>

03/29/2008- Bayer AG said that a new trial on Trasylol had to be halted because the risk of death increased due to excessive bleeding. In addition to this new trial, previous studies have shown that Trasylol has a strong link to kidney failure in patients administered the drug when undergoing heart bypass surgery. More>>>

03/14/2008 - Can you imagine what would happen if three jumbo jets crashed in one month? A thousand people dead. Uproar at the FAA. Planes grounded. Immediate comprehensive inspections of all aircraft. Congressional hearings and investigations. Everything possible would be done to immediately assure public safety. More>>>

02/27/2008 - Congress got an earful today as it held hearings on legislation that would provide more funding and authority to the Food and Drug Administration (FDA). More>>>

02/26/2008 — Two studies published in the New England Journal of Medicine have linked the drug Trasylol, used to reduce bleeding during open-heart surgery, to an increased risk of death and kidney damage among other concerns. More>>>

02/26/2008 — A recent study found that patients that received Bayer's Trasylol during heart surgery were significantly more likely to die within the next decade. More>>>

02/19/2008 — We got a free preview of plaintiffs' opening statement when "60 Minutes," following its victims-and-villains storyline, makes much of the fact Bayer didn't reveal the existence of an unfavorable Trasylol study to the FDA at a September 21 advisory committee meeting. More>>>

02/17/2008 —This is the story of a drug that was on the market for 14 years and may have contributed to the deaths of thousands of patients. Trasylol, made by Bayer, is given in the operating room to control bleeding. It was a big money maker. More>>>

02/15/2008 —The lives of 22,000 patients could have been saved if U.S. regulators had been quicker to remove a Bayer AG drug used to stem bleeding during open heart surgery, according to a medical researcher interviewed by CBS Television's 60 Minutes program. More>>>

02/15/2008 — A renowned researcher calculates that 22,000 patients could have been saved if the Food and Drug Administration removed the heart surgery drug Trasylol two years ago, when his study revealed widespread death associated with it. More>>>

02/11/2008 - The risk of renal dysfunction after aprotinin (Trasylol) was used during heart surgery appears limited to patients also given ACE inhibitors during an off-pump bypass, suggested a retrospective analysis here. More>>>

02/11/2008 - A new retrospective analysis of patients undergoing CABG in whom the antifibrinolytic aprotinin (Trasylol, Bayer) was used has found that the product appears to be safe during on-pump CABG surgery. More>>>

02/08/2008 - Bayer AG's Trasylol, an anti-bleeding drug that was pulled off the market last year, is safe when used during a certain type of cardiac surgery, researchers said. More>>>

02/07/2008 - The blood saving-drug aprotinin appears safe during on-pump cardiac surgery. However, the combination of aprotinin and angiotensin-converting enzyme (ACE) inhibitors during off-pump cardiac surgery is associated with a significant risk of postoperative renal dysfunction. More>>>

12/21/2007 - The licence for Trasylol (aprotinin) has been suspended on the advice of the Commission on Human Medicines (CHM). Global marketing of the drug had already been suspended voluntarily by the marketing authorisation holders (Bayer plc and Nordic Pharma) due to safety concerns.

More>>>

11/29/2007 - The UK's Commission on Human Medicines (CHM) says that the UK marketing authorisation for Bayer AG's (NYSE:BAY) Trasylol, the anti-bleeding drug, should be suspended pending the outcome of a full Europe-wide review of the balance of risks and benefits. More>>>

11/23/2007 - Just a few weeks after Bayer decided to halt global marketing of Trasylol, advisors to Europe’s regulators has issued a statement saying that the blood loss agent should indeed be pulled. More>>>

11/18/2007 - The Food and Drug Administration has tallied at least 235 reports of deaths linked to the blood-clotting drug Trasylol, officials told The Post. More>>>

11/09/2007 - The German pharmaceutical giant Bayer AG announced this week that it would withdraw its controversial heart surgery drug, Trasylol, from the market, after studies found that the use of this drug increased heart surgery death rates by 50 percent. Thus, Trasylol has been added to a mounting pile of banished products, including the once-popular pain reliever Vioxx. More>>>

11/08/2007 - Bayer is suspending global marketing of its clotting drug Trasylol as the FDA waits for additional data from a study that suggested the drug was associated with an increased risk of death. More>>>

11/08/2007 - The German pharmaceutical giant Bayer AG announced this week that it would withdraw its controversial heart surgery drug, Trasylol, from the market, after studies found that the use of this drug increased heart surgery death rates by 50 percent. More>>>

11/07/2007 - Local heart surgeons were unwilling yesterday to dismiss the usefulness of the anti-bleeding drug that was withdrawn from the market earlier this week, though they said they have used it only in rare cases. More>>>

11/06/2007 - FDA announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol (aprotinin injection), a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death. More>>>

11/06/2007 - Under pressure from government regulators around the world, Bayer announced yesterday that it is suspending global sales of a drug widely used to control bleeding during heart surgery, after a study found that patients receiving the medication were at increased risk of dying compared with those who received two other drugs. More>>>

11/06/2007 - Germany's Bayer has temporarily suspended global sales of its anti-bleeding drug Trasylol, which has been linked to a higher risk of death, pending final results of a Canadian study on the medicine. More>>>

11/05/2007 - The U.S. Food and Drug Administration (FDA) today announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery More>>>

11/05/2007 - Pressured by drug regulators from around the world, Bayer announced today that it had agreed to withdraw its controversial heart surgery drug Trasylol after a Canadian study found that it may increase the risk of death. More>>>

11/05/2007 - The U.S. Food and Drug Administration has temporarily halted the use ofthe drug Trasylol, which is used to control bleeding during heart surgery. More>>>

11/05/2007 - Bayer AG, Germany's largest drugmaker, will stop selling its Trasylol bleeding treatment after a study linked the product to a higher risk of death than competitors. More>>>

11/05/2007 - Bayer AG will take its blood-clotting injection Trasylol off the shelves from U.S. stores after the Food and Drug Administration announced that it will reexamine the drug's side effects, according to published reports Monday. More>>>

11/05/2007 - Bayer AG said it will temporarily suspend the sale of blood-clotting injection Trasylol worldwide, after a study in Canada was interrupted last month because experts said the drug exposed trial participants to an increased risk of death. More>>>

11/05/2007 - Following consultation with the German Federal Institute for Drugs and Medical Devices (BfArM), the U.S. Food and Drug Administration (FDA), Health Canada, and other health authorities, Bayer announced today that it has elected to temporarily suspend worldwide marketing of Trasylol More>>>

10/27/2007 - FDA issued an Early Communication about an Ongoing Safety Review of Aprotinin Injection (marketed as Trasylol), a drug used to control bleeding during heart surgery. More>>>

10/27/2007 - Heart surgery antifibrinolytic drug Trasylol, used to control bleeding in high risk surgery patients, has been halted. More>>>

10/27/2007 - Only last month the US Food and Drug Administration (FDA) panel had suggested that aprotinin, sold by Bayer AG under brand name Trasylol, be allowed to remain in market despite reports of increased risk of death and other serious side effect. More>>>

10/27/2007 - The Food and Drug Administration (FDA) has issued a statement informing that the antifibrinolytic drug, Trasylol (aprotinin), appears to increase the risk of death. More>>>  

10/26/2007 - A Canadian trial involving the antifibrinolytic drug Trasylol (aprotinin), used to control bleeding in high risk heart surgery patients has been halted. More>>>

10/26/2007 - Excess 30-day mortality in the aprotinin (Trasylol) arm of an ongoing heart surgery trial discovered by an interim safety analysis has forced researchers to shut down the aprotinin arm of the trial. More>>>

10/26/2007 - Today Bayer announced new guidance to physicians and health care providers regarding the use of Trasylol® (aprotinin injection) in patients at an increased risk of blood loss and blood transfusion undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB). More>>>

10/26/2007 - Bayer AG, one of the world’s leading healthcare and medical product manufacturer on Thursday issued fresh guidelines to physicians for its anti-clotting drug Trasylol, after BART Executive Committee halted its Canadian trial over concerns of increased mortality risk. More>>>

10/26/2007 - Drug giant Bayer Inc. confirmed Thursday that a large Canadian-led trial studying its drug Trasylol (aprotinin) has been halted because of concerns the drug increased the risk of death among people who received it.  More>>>

10/25/2007 - Trasylol, a clotting drug used to prevent excessive bleeding during heart bypass surgery, increases the risk of death when compared with other drugs, the U.S. Food and Drug Administration (FDA) warned Thursday. More>>>

10/25/2007 - Increasing mortality throughout the first 30 days of a randomized trial among surgical patients who received aprotinin (Trasylol, Bayer), compared with other antifibrinolytic agents, has put the brakes on further enrollment, announced the US Food and Drug Administration, which said it received the news on October 19, 2007 from the study's data safety monitoring board. More>>> t the drug may present an untoward risk have been reported frequently.

10/25/2007 - U.S. regulators on Thursday said a trial of Bayer AG's heart surgery drug Trasylol found an increased risk of death from bleeding linked to the treatment. More>>>

10/25/2007 - Bayer Thursday said it issued additional guidance to physicians on Trasylol after the BART Executive Committee halted a Canada-based trial being conducted in cardiac surgery patients. More>>>

10/25/2007 - The US Food and Drug Administration said it will re-evaluate Bayer AG's (NYSE:BAY) Trasylol blood-clotting injection after an independent panel on drug safety warned it of an increased risk of death from the drug. More>>>

10/25/2007 - The U.S. Food and Drug Administration has revealed that the safety board overseeing a large Canadian-led trial has recommended the trial be stopped because of concerns the drug being tested increases the risk of death. More>>>

10/25/2007 - On October 19, 2007, FDA was notified of the Data Safety Monitoring Board’s (DSMB) recommendation to stop patient enrollment in the aprotinin (marketed as Trasylol by Bayer, Inc.) More>>>

10/21/2007 - Joseph Randone suffered a horrible death because pharmaceutical giant Bayer Corp. hid the lethal side effects of its highly profitable heart-surgery drug, a new suit alleges. More>>>

09/27/2007 - The U.S. Food and Drug Administration has recommended that additional clinical trials be conducted on a drug used locally in heart surgeries after finding patients who took it had a higher risks of serious side effects including kidney problems, heart attacks and strokes. More>>>

09/18/2007 - Largely as a result of high-profile drug safety problems such as Vioxx and Avandia, House and Senate versions of the reauthorization of the Prescription Drug Fee Users Act contain key provisions about post-market studies, the registration of clinical trials and the public release of clinical trial results. More>>>

09/12/2007 - Bayer AG's heart surgery drug, Trasylol, linked in some studies with an increased risk of death, should remain on the market, advisors to the U.S. Food and Drug Administration said on Wednesday. More>>>

09/12/2007 - Bayer’s Trasylol (aprotinin), which surgeons say is appropriate in select patients, is nevertheless under the microscope of an FDA advisory committee today regarding safety issues.

More>>>

09/10/2007 - Bayer AG's heart surgery drug Trasylol appears to increase the risk of kidney failure and the risk of death, U.S. regulators said in documents released on Monday. More>>>

09/10/2007 - FDA regulators said that Bayer's injectable Trasylol, used to control bleeding in bypass surgery, raised the risk of kidney damage in clinical studies and may also increase the chance of death in patients. More>>>

09/10/2007 - A Bayer Pharmaceuticals drug used to control bleeding in patients undergoing heart bypass surgery will face a second safety review by a Food and Drug Administration panel Wednesday. More>>>

08/17/2007 - Bayer's failure to supply U.S. regulators with risk data for heart-surgery drug Trasylol was the result of misjudgement, not a cover-up, an independent counsel hired by the German drugmaker said. More>>>

08/04/2007 - When William "Sonny" Morrill went in for heart bypass surgery, his wife was so sure he would recover she bought him new pajamas. But three days after the operation, the 61-year-old Sarasota resident died from kidney failure and a triple whammy of heart attacks. More>>>

02/10/2007 - A drug widely used to prevent excessive bleeding during heart surgery appears to raise the risk of dying in within five years by nearly 50 percent, an international study found. More>>>

02/09/2007 - Patients undergoing cardiac surgery who are given a drug widely used to limit blood loss are almost 50per cent more likely to die than those who do not receive the drug. More>>>

Ennis & Ennis, P.A. is representing individuals that have been harmed as a result of Trasylol side effects. If you or a loved one have suffered as a result of Trasylol side effects such as kidney failure, heart attack, or stroke you may be entitled to compensation. For more information about a Trasylol lawsuit, a possible Trasylol recall, or for questions regarding Trasylol class action lawsuits click here for a free, confidential case evaluation.